GlobalData on MSN2d
Vaxcyte enters final stage of Phase II pneumococcal vaccine trial in infants
Vaxcyte has advanced to the Phase II trial’s second and final stage (Stage 2) assessing its 31-valent pneumococcal conjugate ...
Asia News Network2d
Brunei introduces pneumococcal vaccine for infants, children
With this addition, the Sultanate's immunisation programme now includes 12 vaccines to prevent 12 vaccine-preventable diseases. Vaccinations under the programme are provided free of charge at Maternal ...
The Pharma Letter3d
Uvax Bio appoints Kevin O’Neill as interim chief executive
Uvax Bio, a privately held vaccine developer founded in 2018 as a spin-off from Scripps Research, has appointed chief ...
Zacks.com on MSN4d
Merck Q4 Earnings & Sales Beat Estimates, Stock Down on Weak '25 View
Merck MRK reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.72, which beat the Zacks Consensus Estimate of $1.69. In the year-ago period, management reported adjusted EPS of 3 cents ...
MRK Gets Positive CHMP Nod for 21-Valent Pneumococcal Jab Capvaxive
The Committee for Medicinal Products for Human Use recommends approval for Merck's pneumococcal 21-valent conjugate vaccine, ...